This Week in Obstetrics & Gynecology — Oct 29, 2026
Generated Oct 30, 2026 · 11:13
The week's practice-changing Obstetrics & Gynecology research, summarized for clinicians.
If the audio fails to play, refresh the page to renew the link.
Get next week’s Obstetrics & Gynecology briefing — free.
In your podcast app, or readable in your inbox with the audio one tap away.
In Vitro Fertilization or Intrauterine Insemination in Unexplained Infertility.
In unexplained infertility, one IVF cycle yielded more live births within seven months than four insemination cycles, but cumulative live-birth rates converged near 70 percent by twenty months.
New England Journal of Medicine · 2026 · PubMed
This week’s papers
- 01
In Vitro Fertilization or Intrauterine Insemination in Unexplained Infertility.
In unexplained infertility, one IVF cycle yielded more live births within seven months than four insemination cycles, but cumulative live-birth rates converged near 70 percent by twenty months.
Prentice LR et al. · New England Journal of Medicine · 2026
From the briefingIf you only have time for one paper this week, make it the New England Journal of Medicine trial comparing insemination with IVF in unexplained infertility [1]. It directly tests the first-line recommendation in international guidelines and shows that the real difference is speed and risk rather than eventual success, a distinction that reshapes the counseling conversation.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 02
IVF versus surgery for infertility in women with deep and ovarian endometriosis: a partially randomized patient preference trial.
In infertile women with ultrasound-diagnosed ovarian or deep endometriosis, IVF roughly doubled live births within a year compared with surgery, prompting early trial termination.
Benaglia L et al. · American Journal of Obstetrics & Gynecology · 2026
From the briefingIn the American Journal of Obstetrics and Gynecology, Benaglia and colleagues addressed women with ultrasound-diagnosed ovarian and deep endometriosis, comparing surgery followed by natural conception against up to three IVF cycles in a partially randomized patient preference trial at three Italian referral centers [2]. Recruitment was stopped early after 130 women because IVF looked clearly better. In the randomized cohort, live births within a year occurred in 57 percent of the IVF group versus 26 percent of the surgery group, roughly doubling the chance of a live birth, and the preference cohort showed almost the same effect. The randomized arm included only 55 women, and eligibility was narrow: under 40, endometriomas under four centimetres, no prior surgery, normal semen analysis. Within those limits, the trial supports IVF over surgery when the goal is pregnancy, though it says nothing about pain outcomes.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 03
First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial.
First-line pembrolizumab alone markedly extended progression-free survival over chemotherapy in mismatch repair-deficient endometrial cancer with fewer severe toxicities, though overall survival was not yet significant.
Slomovitz BM et al. · The Lancet · 2026
From the briefingSlomovitz and colleagues report the interim analysis of KEYNOTE-C93, which randomized 299 patients with mismatch repair-deficient advanced or recurrent disease to first-line pembrolizumab alone or carboplatin plus paclitaxel [3]. Median progression-free survival was about 38 months with pembrolizumab versus about 8 months with chemotherapy, and at three years roughly half of patients on pembrolizumab remained progression-free compared with under a third on chemotherapy. Severe treatment-related adverse events fell from about half of chemotherapy patients to under a fifth of pembrolizumab patients, with far less alopecia, anaemia and neuropathy. Overall survival did not meet its significance threshold at this interim look, and, as the authors acknowledge, the comparator was chemotherapy alone rather than the current standard of immunotherapy plus chemotherapy. So the trial establishes a chemotherapy-free option for this molecular subgroup but cannot say whether it matches the combination.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 04
Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial.
A phase 3 trial of 776 patients compared a TROP2-directed antibody-drug conjugate with doxorubicin or paclitaxel after platinum and immunotherapy in endometrial cancer; efficacy results require the full report.
Lorusso D et al. · The Lancet · 2026
From the briefingAlso in The Lancet, Lorusso and colleagues report TroFuse-005, randomizing 776 patients whose endometrial cancer had progressed after platinum chemotherapy and immunotherapy to sacituzumab tirumotecan, an antibody-drug conjugate targeting the trophoblast cell-surface antigen 2, or physician's choice of doxorubicin or paclitaxel, with progression-free and overall survival as dual primary endpoints [4]. The abstract available to us is truncated before the efficacy results, so we cannot report the outcome here; listeners will want to go to the full paper for the numbers.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 05
Low-grade serous ovarian cancer: 2026 expert consensus report.
An international consensus positions chemotherapy-containing postoperative therapy as reference for stage II-IV low-grade serous ovarian cancer and integrates avutometinib-defactinib for KRAS-mutated recurrence.
Grisham RN et al. · Gynecologic Oncology · 2026
From the briefingRounding out the oncology theme, Grisham and colleagues in Gynecologic Oncology publish a 2026 international consensus on low-grade serous ovarian cancer [5]. The update positions chemotherapy-containing postoperative therapy, based on NRG-GY019, as the reference approach for stage two to four disease, while allowing endocrine monotherapy as individualized de-escalation in selected cases. For recurrence, it incorporates the United States Food and Drug Administration's accelerated approval of avutometinib with defactinib for KRAS-mutated disease and emerging data on endocrine therapy combined with CDK4 and 6 inhibition. As consensus, it carries expert rather than trial-level weight.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 06
Loop electrosurgical excision procedure with or without intraoperative iodine: A randomized controlled trial.
In a randomized trial of 229 women, Lugol's iodine staining during loop excision roughly doubled involved resection margins without improving pain or satisfaction, arguing against routine use.
Hecken JM et al. · American Journal of Obstetrics & Gynecology · 2026
From the briefingStaying with the cervix, a small procedural trial challenges a common habit. In the American Journal of Obstetrics and Gynecology, Hecken and colleagues randomized 229 women undergoing loop electrosurgical excision to intraoperative Lugol's iodine staining or no staining [6]. Involved resection margins occurred in about 18 percent of the iodine group versus 7 percent of controls, roughly two and a half times as often, and the association strengthened after adjustment. A post hoc analysis suggested shallower cones with iodine, a plausible mechanism. Bleeding in the first days was somewhat lighter with iodine, but pain and satisfaction did not differ. This is a single-center trial, but as the first head-to-head randomized comparison it argues against routine staining, which the authors explicitly conclude.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 07
Low-Dose Aspirin in the Prevention of Recurrent Spontaneous Preterm Birth Stratified by Placental Maternal Vascular Malperfusion: Secondary Analysis of a Randomized Trial.
In a small secondary analysis, low-dose aspirin sharply reduced recurrent preterm birth only in women whose prior placenta showed maternal vascular malperfusion, with no benefit otherwise.
Meliëzer JAL et al. · BJOG · 2026
From the briefingIn BJOG, Meliëzer and colleagues revisited the Dutch APRIL trial, which tested low-dose aspirin against placebo for preventing recurrent spontaneous preterm birth [7]. Among women whose prior preterm placenta showed maternal vascular malperfusion, recurrent preterm birth occurred in one of 24 women on aspirin versus nine of 20 on placebo, roughly a ninety percent reduction. In women without malperfusion, there was no benefit, and the rate was numerically higher on aspirin, though not significantly. This is a secondary analysis covering only the 41 percent of participants with available histology, with 44 women in the key subgroup, so it is hypothesis-generating; it does, however, suggest placental pathology could identify a vascular phenotype that responds to aspirin.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 08
Antidepressant Discontinuation During Pregnancy and Risk of Mental Health-Related Emergencies.
Among privately insured patients with preexisting depression or anxiety, stopping SSRIs or SNRIs in pregnancy was common and associated with more mental health emergency visits through postpartum.
Zafman KB et al. · Obstetrics & Gynecology · 2026
From the briefingIn Obstetrics and Gynecology, Zafman and colleagues used Pennsylvania private insurance claims to examine 1,462 patients entering pregnancy on an SSRI or SNRI [8]. Nearly two thirds of these patients had a treatment gap of more than 60 days, most often in the first trimester. Discontinuation was associated with more behavioral health emergency visits, roughly double in the ninth month, and the excess persisted for eight months postpartum. Pre-pregnancy visit rates were similar between groups, which partly addresses confounding, but this remains observational claims data with bivariate comparisons.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 09
Pregnancy Outcomes After Living Kidney Donation.
Pregnancies after living kidney donation had about 50 percent higher risk of hypertensive disorders and nearly double small-for-gestational-age births, though most remained uncomplicated.
Wang C et al. · JAMA · 2026
From the briefingIn JAMA, Wang and colleagues matched 385 pregnancies in Canadian living kidney donors to 1,540 nondonor pregnancies [9]. Hospitalization for gestational hypertension, preeclampsia or eclampsia occurred in about 12 percent of donor pregnancies versus 8 percent of nondonor pregnancies, about a fifty percent relative increase, and small-for-gestational-age birth was nearly twice as common. The authors stress that most donor pregnancies were uncomplicated, and they frame the findings as informing donor counseling and prenatal care.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 10
Mate Whenua-Follow-Up After Early Medical Abortion in New Zealand: A Randomised Controlled Trial.
Urine self-assessment after early medical abortion achieved complete follow-up in about 95 percent versus two thirds with serum hCG, without increasing complications.
Wise MR et al. · BJOG · 2026
From the briefingFinally, a second New Zealand trial, in BJOG, from Wise and colleagues randomized 732 people having early medical abortion to self-assessment with a low-sensitivity urine pregnancy test or serial serum hCG [10]. Complete follow-up reached about 95 percent with self-assessment versus about two thirds with blood tests, successful abortion was also more common, and complications did not differ, though self-assessment led to more additional investigations. One ongoing pregnancy was detected after the first trimester. The authors recommend self-assessment, highlighting equity benefits for people facing barriers to laboratory access.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
The full briefing
This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice.
Welcome to This Week in Obstetrics & Gynecology. This week we're covering 10 notable papers spanning first-line fertility treatment, a shifting landscape in gynecologic cancer care, and pregnancy risk and follow-up in specific populations. Let's dive in.
We start with fertility, where two trials ask whether in vitro fertilization should move earlier in the treatment pathway. In the New England Journal of Medicine, Prentice and colleagues ran a multicenter randomized trial of 737 couples with unexplained infertility in New Zealand, comparing up to four cycles of intrauterine insemination with ovarian stimulation against one complete IVF cycle with transfer of all embryos. Over the first seven months, the cumulative live-birth rate was 31 percent with insemination and 55 percent with IVF, a gap of about 24 percentage points, so insemination failed to show noninferiority by a wide margin [1]. The longer view tempers that headline. Couples who did not conceive could cross into further IVF, and over twenty months the cumulative live-birth rates converged at around 70 percent in both arms. Serious adverse events, mostly related to oocyte retrieval or hyperstimulation, were more than twice as common in the IVF arm, at 14 couples versus 6. The trial does not overturn guidelines recommending insemination first, but it reframes the trade-off as one of time to pregnancy, cost and procedural risk rather than ultimate success, and couples omitted during pandemic lockdowns are a caveat on the primary analysis. In the American Journal of Obstetrics and Gynecology, Benaglia and colleagues addressed women with ultrasound-diagnosed ovarian and deep endometriosis, comparing surgery followed by natural conception against up to three IVF cycles in a partially randomized patient preference trial at three Italian referral centers [2]. Recruitment was stopped early after 130 women because IVF looked clearly better. In the randomized cohort, live births within a year occurred in 57 percent of the IVF group versus 26 percent of the surgery group, roughly doubling the chance of a live birth, and the preference cohort showed almost the same effect. The randomized arm included only 55 women, and eligibility was narrow: under 40, endometriomas under four centimetres, no prior surgery, normal semen analysis. Within those limits, the trial supports IVF over surgery when the goal is pregnancy, though it says nothing about pain outcomes.
Our second theme is gynecologic oncology, where two large phase 3 trials in The Lancet target advanced endometrial cancer at opposite ends of the treatment pathway. Slomovitz and colleagues report the interim analysis of KEYNOTE-C93, which randomized 299 patients with mismatch repair-deficient advanced or recurrent disease to first-line pembrolizumab alone or carboplatin plus paclitaxel [3]. Median progression-free survival was about 38 months with pembrolizumab versus about 8 months with chemotherapy, and at three years roughly half of patients on pembrolizumab remained progression-free compared with under a third on chemotherapy. Severe treatment-related adverse events fell from about half of chemotherapy patients to under a fifth of pembrolizumab patients, with far less alopecia, anaemia and neuropathy. Overall survival did not meet its significance threshold at this interim look, and, as the authors acknowledge, the comparator was chemotherapy alone rather than the current standard of immunotherapy plus chemotherapy. So the trial establishes a chemotherapy-free option for this molecular subgroup but cannot say whether it matches the combination. Also in The Lancet, Lorusso and colleagues report TroFuse-005, randomizing 776 patients whose endometrial cancer had progressed after platinum chemotherapy and immunotherapy to sacituzumab tirumotecan, an antibody-drug conjugate targeting the trophoblast cell-surface antigen 2, or physician's choice of doxorubicin or paclitaxel, with progression-free and overall survival as dual primary endpoints [4]. The abstract available to us is truncated before the efficacy results, so we cannot report the outcome here; listeners will want to go to the full paper for the numbers. Rounding out the oncology theme, Grisham and colleagues in Gynecologic Oncology publish a 2026 international consensus on low-grade serous ovarian cancer [5]. The update positions chemotherapy-containing postoperative therapy, based on NRG-GY019, as the reference approach for stage two to four disease, while allowing endocrine monotherapy as individualized de-escalation in selected cases. For recurrence, it incorporates the United States Food and Drug Administration's accelerated approval of avutometinib with defactinib for KRAS-mutated disease and emerging data on endocrine therapy combined with CDK4 and 6 inhibition. As consensus, it carries expert rather than trial-level weight.
Staying with the cervix, a small procedural trial challenges a common habit. In the American Journal of Obstetrics and Gynecology, Hecken and colleagues randomized 229 women undergoing loop electrosurgical excision to intraoperative Lugol's iodine staining or no staining [6]. Involved resection margins occurred in about 18 percent of the iodine group versus 7 percent of controls, roughly two and a half times as often, and the association strengthened after adjustment. A post hoc analysis suggested shallower cones with iodine, a plausible mechanism. Bleeding in the first days was somewhat lighter with iodine, but pain and satisfaction did not differ. This is a single-center trial, but as the first head-to-head randomized comparison it argues against routine staining, which the authors explicitly conclude.
Our final theme covers pregnancy risk in specific populations and the logistics of follow-up. In BJOG, Meliëzer and colleagues revisited the Dutch APRIL trial, which tested low-dose aspirin against placebo for preventing recurrent spontaneous preterm birth [7]. Among women whose prior preterm placenta showed maternal vascular malperfusion, recurrent preterm birth occurred in one of 24 women on aspirin versus nine of 20 on placebo, roughly a ninety percent reduction. In women without malperfusion, there was no benefit, and the rate was numerically higher on aspirin, though not significantly. This is a secondary analysis covering only the 41 percent of participants with available histology, with 44 women in the key subgroup, so it is hypothesis-generating; it does, however, suggest placental pathology could identify a vascular phenotype that responds to aspirin. In Obstetrics and Gynecology, Zafman and colleagues used Pennsylvania private insurance claims to examine 1,462 patients entering pregnancy on an SSRI or SNRI [8]. Nearly two thirds of these patients had a treatment gap of more than 60 days, most often in the first trimester. Discontinuation was associated with more behavioral health emergency visits, roughly double in the ninth month, and the excess persisted for eight months postpartum. Pre-pregnancy visit rates were similar between groups, which partly addresses confounding, but this remains observational claims data with bivariate comparisons. In JAMA, Wang and colleagues matched 385 pregnancies in Canadian living kidney donors to 1,540 nondonor pregnancies [9]. Hospitalization for gestational hypertension, preeclampsia or eclampsia occurred in about 12 percent of donor pregnancies versus 8 percent of nondonor pregnancies, about a fifty percent relative increase, and small-for-gestational-age birth was nearly twice as common. The authors stress that most donor pregnancies were uncomplicated, and they frame the findings as informing donor counseling and prenatal care. Finally, a second New Zealand trial, in BJOG, from Wise and colleagues randomized 732 people having early medical abortion to self-assessment with a low-sensitivity urine pregnancy test or serial serum hCG [10]. Complete follow-up reached about 95 percent with self-assessment versus about two thirds with blood tests, successful abortion was also more common, and complications did not differ, though self-assessment led to more additional investigations. One ongoing pregnancy was detected after the first trimester. The authors recommend self-assessment, highlighting equity benefits for people facing barriers to laboratory access.
If you only have time for one paper this week, make it the New England Journal of Medicine trial comparing insemination with IVF in unexplained infertility [1]. It directly tests the first-line recommendation in international guidelines and shows that the real difference is speed and risk rather than eventual success, a distinction that reshapes the counseling conversation.
Here is what this week's evidence adds up to in Obstetrics & Gynecology. First, IVF achieves pregnancy faster than insemination in unexplained infertility and outperforms surgery in selected women with endometriosis, but cumulative success over time can converge and both trials have specific populations and limitations. Second, single-agent pembrolizumab offers a chemotherapy-free first-line option with markedly longer progression-free survival in mismatch repair-deficient endometrial cancer, although overall survival is immature and comparison with immunotherapy plus chemotherapy is still missing. Third, a single randomized trial suggests iodine staining during loop excision increases involved margins, the first randomized evidence against a widespread practice. Fourth, observational and secondary-analysis data point to identifiable risk groups in pregnancy, including kidney donors, patients stopping antidepressants, and women with placental vascular malperfusion who may respond to aspirin, but none of these findings is yet trial-confirmed. Fifth, urine self-assessment after early medical abortion improved follow-up without more complications in a randomized trial.
That's your roundup for This Week in Obstetrics & Gynecology. The full transcript and references are available on the episode page. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.
If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And if it saves you time, a quick rating in your podcast app helps other physicians find the show.
This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.
Spot something worth flagging?
Get this every week in your podcast app — free.
New obstetrics_gynecology episodes land in your feed automatically — listen on your commute.